Artwork

Content provided by Practicing Clinicians Exchange. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Practicing Clinicians Exchange or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

ASCO 2022: Advances in CLL/SLL

37:17
 
Share
 

Manage episode 333078083 series 3264057
Content provided by Practicing Clinicians Exchange. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Practicing Clinicians Exchange or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

  • Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
  • Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
  • Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
    Obinutuzumab + Chlorambucil as first-line therapy in CLL
  • Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

  continue reading

90 episodes

Artwork
iconShare
 
Manage episode 333078083 series 3264057
Content provided by Practicing Clinicians Exchange. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Practicing Clinicians Exchange or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

  • Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
  • Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
  • Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
    Obinutuzumab + Chlorambucil as first-line therapy in CLL
  • Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

  continue reading

90 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play